Mpox virus antigens (MPXV antigens)

Mpox virus (MPXV) antigens encompass a diverse group of structural and non-structural proteins that are critical for the viral life cycle and represent the primary targets for vaccines and therapeutics [1]. Key structural antigens include A29L, which facilitates viral attachment, and M1R, which is involved in membrane fusion, while non-structural proteins such as the E9L DNA polymerase drive viral replication [2][3]. In the context of preventive medicine, vaccines like JYNNEOS utilize these antigens to elicit a robust neutralizing antibody response that protects against infection [4]. Small-molecule therapeutics specifically target certain antigens to halt disease progression; for instance, tecovirimat inhibits the VP37 protein (F13L), which is essential for the formation of extracellular enveloped virions and their dissemination within the host [5]. Brincidofovir and cidofovir act by inhibiting the E9L antigen's polymerase activity, effectively stopping genomic replication [6]. Understanding the molecular structure and variability of these antigens is vital for biotech development, as mutations in these targets can lead to drug resistance or reduced vaccine efficacy [1][5].

Other names

Monkeypox virus antigensMPXV proteinsOrthopoxvirus antigensMpox viral proteins

Inhibition of the VP37 envelope wrapping protein (encoded by the F13L gene) to prevent the egress of extracellular enveloped virions; inhibition of the viral DNA polymerase (encoded by the E9L gene) to terminate viral DNA synthesis; and induction of active immunity through the presentation of structural antigens like A29L, M1R, and B5R to the host immune system via vaccination.